part time job

Elevar Announces Results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-Stage Gastric Cancer Patients

SALT LAKE CITY, Sept. 29, 2019 /PRNewswire/ — Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2…